ALT alanine aminotransferase
BSA Body surface area
CR Complete response
CTCAE Common Terminology Criteria for Adverse Events
ctDNA Circulating tumor DNA
DLT Dose limiting toxicity
EFS Event free survival
EKG Electrocardiogram
EWS Ewing sarcoma
IV Intravascular
MTD Maximum tolerated dose
mTKI multitargeted kinase inhibitors
PR Partial response
RECIST Response Evaluation Criteria in Solid Tumors
RP2D recommended phase 2 dose
RTK Receptor tyrosine kinase
SD Stable disease
TRAE treatment related adverse effect
VEGFR-2 vascular endothelial growth factor receptor 2
ULP-WGS ultra-low passage whole genome sequencing
UPC urine protein/creatinine